Fundamental Analysis of MDxHealth SA(EBR:MDXH) stock

Fundamental Rating

Overall MDXH gets a fundamental rating of 2 out of 10. We evaluated MDXH against 79 industry peers in the Biotechnology industry. MDXH may be in some trouble as it scores bad on both profitability and health. MDXH is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MDXH has reported negative net income.

In the past 5 years MDXH always reported negative net income.

In the past 5 years MDXH always reported negative operating cash flow.

1.2 Ratios

MDXH has a worse Return On Assets (-51.61%) than 63.64% of its industry peers.

The Return On Equity of MDXH (-393.48%) is worse than 75.32% of its industry peers.

		Industry Rank	Sector Rank
ROA	-51.61%
ROE	-393.48%
ROIC	N/A

ROA(3y)-55.15%

ROA(5y)-64.23%

ROE(3y)-343.17%

ROE(5y)-262.12%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With a decent Gross Margin value of 59.66%, MDXH is doing good in the industry, outperforming 64.94% of the companies in the same industry.

In the last couple of years the Gross Margin of MDXH has declined.

The Profit Margin and Operating Margin are not available for MDXH so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	59.66%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-6.79%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, MDXH has more shares outstanding

The number of shares outstanding for MDXH has been increased compared to 5 years ago.

MDXH has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -3.05, we must say that MDXH is in the distress zone and has some risk of bankruptcy.

MDXH has a Altman-Z score of -3.05. This is in the lower half of the industry: MDXH underperforms 71.43% of its industry peers.

A Debt/Equity ratio of 2.17 is on the high side and indicates that MDXH has dependencies on debt financing.

MDXH's Debt to Equity ratio of 2.17 is on the low side compared to the rest of the industry. MDXH is outperformed by 75.32% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	2.17
Debt/FCF	N/A
Altman-Z	-3.05

ROIC/WACCN/A

WACC6.93%

2.3 Liquidity

A Current Ratio of 2.43 indicates that MDXH has no problem at all paying its short term obligations.

The Current ratio of MDXH (2.43) is comparable to the rest of the industry.

A Quick Ratio of 2.27 indicates that MDXH has no problem at all paying its short term obligations.

MDXH has a Quick ratio (2.27) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	2.43
Quick Ratio	2.27

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for MDXH have decreased strongly by -16.81% in the last year.

Looking at the last year, MDXH shows a very strong growth in Revenue. The Revenue has grown by 66.59%.

The Revenue has been decreasing by -1.77% on average over the past years.

EPS 1Y (TTM)-16.81%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-700%

Revenue 1Y (TTM)66.59%

Revenue growth 3Y46.47%

Revenue growth 5Y-1.77%

Revenue growth Q2Q73.48%

3.2 Future

The Earnings Per Share is expected to grow by 51.91% on average over the next years. This is a very strong growth

MDXH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.69% yearly.

EPS Next Y-6519.8%

EPS Next 2Y-619.83%

EPS Next 3Y-49.87%

EPS Next 5Y51.91%

Revenue Next Year84.81%

Revenue Next 2Y47.5%

Revenue Next 3Y43.11%

Revenue Next 5Y27.69%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MDXH. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDXH. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

MDXH's earnings are expected to decrease with -49.87% in the coming years. This may justify a cheaper valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-619.83%

EPS Next 3Y-49.87%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MDXH!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MDxHealth SA

EBR:MDXH (12/15/2023, 7:00:00 PM)

3.02

-0.12 (-3.76%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap82.41M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-51.61%
ROE	-393.48%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	59.66%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.66

Health

		Industry Rank	Sector Rank
Debt/Equity	2.17
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	2.43
Quick Ratio	2.27
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-16.81%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-6519.8%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)66.59%

Revenue growth 3Y46.47%

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

MDxHealth SA (MDXH.BR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens